Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer-;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients,...
American Association for Cancer Research Dec 11 2024 Imlunestrant, an investigational next-generation selective estrogen receptor degrader , improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer -;as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib in all patients, regardless of ESR1 mutation status-;according to results from the phase III EMBER-3 clinical trial presented at the...
Unlike fulvestrant, imlunestrant can be taken orally and can penetrate the blood-brain barrier, offering the possibility of targeting central nervous system metastases, explained Jhaveri, who is also an associate professor at Weill Cornell Medical College. "These promising results mean that imlunestrant is potentially another single-agent option for the many patients whose recurrent breast cancers harbor ESR1 mutations," said Jhaveri.
Imlunestrant was well tolerated, both as monotherapy and in combination, Jhaveri said. Imlunestrant showed favorable safety profile, with generally low-grade and manageable adverse events, and without the oral SERD-specific safety signals of ocular or cardiac issues. The safety profile of the combination was consistent with the known fulvestrant-abemaciclib profile with a relatively low discontinuation rate of 6.3% that compares favorably to available combination regimens.
Cancer Aromatase Inhibitor Biotechnology Brain Clinical Trial Efficacy Endocrine Estrogen Medicine Mutation Oncology Pharmaceuticals Receptor Research Therapeutics
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancerOne-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis.
Read more »
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancerOne-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis.
Read more »
This Is Exactly When You Should Worry About Breast LumpsBreast cancer is only diagnosed in 10% of new breast lumps.
Read more »
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patientsA new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.
Read more »
Biomarker discovery offers hope for aggressive breast cancer treatmentA new study led by Lund University in Sweden has solved a years-old mystery: which patients with aggressive breast cancer are helped by a targeted cancer treatment that had been under development but was shelved.
Read more »
New vaccine shows potential in preventing recurrence of triple-negative breast cancerA small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.
Read more »